Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

NCT05239910 | Withdrawn Phase 2 DMC FDA Drug

• 1 other identifier: RP6530+CHOP-2103
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group 2: 800mg BID) when given with standard regimen of CHOP, followed by single agent maintenance treatment with tenalisib for 1 year. Recruitment of 20 patients each will be done in both groups in parallel. All eligible patients will start with a run-in period, in which single agent tenalisib will be administered for 3 cycles of 21 days each. Post run-in period, all patients will proceed to receive tenalisib and CHOP regimen for next 6 cycles. After completion of 6 cycles of T-CHOP treatment, maintenance therapy with tenalisib will be initiated in patients showing CR and PR. These patients will continue to receive single agent tenalisib for 1 year.

Conditions

Peripheral T Cell Lymphoma

Keywords

Tenalisib; RP6530; PI3K

Outcome Measures

Primary Outcomes (1)

• Complete Response (CR) rate at the end of T-CHOP treatment.

  CR rate is defined as the percentage of patients showing complete response as assessed by the Investigator according to the Lugano Classification.

  9 months

Secondary Outcomes (4)

• Overall Response Rate (ORR) at the end of T-CHOP treatment.

  9 months

• Duration of Response (DoR),

  3 years

• Progression-Free Survival (PFS)

  3 years

• Overall Survival (OS)

  3 years

Study Arms (2)

Tenalisib 400 mg BID and CHOP

EXPERIMENTAL

Drug: Tenalisib

Tenalisib 800 mg BID and CHOP

EXPERIMENTAL

Drug: Tenalisib

Interventions

Tenalisib DRUG

Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.

Tenalisib 400 mg BID and CHOP; Tenalisib 800 mg BID and CHOP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of full informed consent prior to any study-specific procedures.
• Pathologically confirmed diagnosis of PTCL according to WHO 2016 classification criteria EXCEPT following subtypes:
• ALK-positive anaplastic T-cell lymphoma; CD30+ PTCL (who are eligible for BV and CHOP combination); extra-nodal NK/T-cell lymphoma, nasal type; HTLV1- associated lymphoma; primary cutaneous anaplastic T-cell lymphoma, T-cell lymphoma with only skin involvement
• Disease status is defined as treatment naïve patients with PTCL who have not received prior systemic therapy for lymphoma.
• Must have ECOG performance status ≤ 2
• Patients must have measurable disease defined as at least one bi-dimensional measurable lesion assessed radiologically with a minimum measurement of \> 1.5 cm in the longest diameter.
• Patients must be fit to receive full-dose CHOP Therapy.
• Adequate bone marrow, liver and renal functions

You may not qualify if:

• Patients who have received prior systemic therapy for lymphoma or are receiving anticancer therapy including any investigational therapy (e.g., chemotherapy, biologic therapy, hormonal therapy).
• Patients with known Central Nervous System (CNS) lymphoma or CNS involvement by lymphoma.
• Active uncontrolled systemic fungal, bacterial or viral infection
• Patient with ongoing or significant cardiac disease in last 6 months which according to the investigator can impact study participation
• Patients with co-morbidities/complications
• Known history of severe liver injury/disease
• Active viral infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. and history of severe cutaneous reactions
• Patient with any other active malignancy at the time of screening except for adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
• Hypersensitivity to the active substance or to any of the excipients.
• Pregnancy or lactation.
• Concurrent medications or substance, the example of these treatment includes strong inhibitors or inducer of CYP3A4 enzyme or substrate of CYP3A4 with narrow therapeutic index.

Sponsors & Collaborators

• Rhizen Pharmaceuticals SA: lead

Study Sites (1)

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

tenalisib

Condition Hierarchy (Ancestors)

Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2022
• First Posted: February 15, 2022
• Study Start: January 1, 2023
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: October 17, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)